Loskutnikov M A, Domashenko M A, Vakin T M, Trushina I A, Konstantinov V I, Proskuryakova O S, Shchukina E P
Magnitogorsk Irong&Steel Clinical Hospital, Magnitogorsk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(10):22-26. doi: 10.17116/jnevro202012010122.
To evaluate the efficacy and safety of sequential therapy with mexidol (solution for intravenous and intramuscular injections) and mexidol forte 250 (coated tablets) in acute and early recovery stages of hemispheric ischemic stroke.
The changes in scores on the modified Rankin Scale (mRs) (primary endpoint), the National Institute of Health Stroke Scale (NIHSS), the Bartel Index (BI), the Montreal Cognitive Assessment (MoCa), the Beck Depression Inventory (BDI), the EuroQol Quality of Lifes Scale ( EQ-5D) were assessed in the end of treatment (secondary endpoint).
Prolonged and sequential therapy with mexidol at the dose 500 mg daily during 14 days (saturation phase) and mexidol forte 250 at the dose of 250 mg three times a day during 60 days (maximum therapeutic effect) provides additional opportunities for a more complete recovery in acute and early recovery stages of hemispheric ischemic stroke (increases quality of life, improves movement and cognitive functions).
